Currently out of the existing stock ratings of Daniil Gataulin, 22 are a BUY (75.86%), 7 are a HOLD (24.14%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin works at CHARDAN CAPITAL with a stock forecast success ratio of 23.81% fulfilled within 108.86 days on average.

Daniil Gataulin’s has documented 54 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on OCGN, Ocugen at 15-May-2024.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on ADVM (ADVERUM BIOTECHNOLOGIES).
The best stock recommendation documented was for ADVM (ADVERUM BIOTECHNOLOGIES) at 11/11/2022. The price target of $2 was fulfilled within 243 days with a profit of $1.23 (159.74%) receiving and performance score of 6.57.

Average potential price target upside

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

22

$13.96 (173.63%)

4

19 days ago

4/5 (80%)

$12.81 (139.39%)

279

Buy

6

$4.05 (207.69%)

4

8 months 14 days ago

4/7 (57.14%)

$4.22 (237.08%)

196

Buy

4

$-4.04 (-50.25%)

2

9 months 7 days ago

4/4 (100%)

$2.11 (111.64%)

432

Hold

3

$-5.04 (-62.69%)

6

1 years 6 months 7 days ago

3/4 (75%)

$2.23 (289.61%)

528

Hold

2

$-6.04 (-75.12%)

5

2 years 9 months 25 days ago

3/3 (100%)

$-0.36 (-15.25%)

397

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Daniil Gataulin is most bullish on?

Potential upside of $36.01 has been obtained for RGNX (REGENXBIO)

Which stock is Daniil Gataulin is most reserved on?

Potential downside of $3.09 has been obtained for OCGN (OCUGEN)

What Year was the first public recommendation made by Daniil Gataulin?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?